Abivax Sees Unusually High Options Volume (NASDAQ:ABVX)

Abivax SA Sponsored ADR (NASDAQ:ABVX) was the recipient of some unusual options trading on Monday. Traders bought 16,006 call options on the stock. This represents an increase of 100% compared to the typical daily volume of 7,985 call options.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on ABVX shares. Morgan Stanley reduced their price objective on shares of Abivax from $145.00 to $132.00 and set an “overweight” rating for the company in a research report on Tuesday, June 2nd. Citizens Jmp increased their target price on shares of Abivax from $131.00 to $187.00 and gave the company a “market outperform” rating in a research note on Tuesday, June 2nd. Citigroup restated an “outperform” rating on shares of Abivax in a report on Tuesday, June 2nd. Wolfe Research set a $136.00 price target on shares of Abivax in a research report on Wednesday, June 3rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Abivax in a report on Monday, April 20th. Twelve research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $130.08.

Abivax Stock Performance

Shares of NASDAQ ABVX traded up $3.15 during trading hours on Monday, hitting $102.30. The stock had a trading volume of 1,676,856 shares, compared to its average volume of 1,437,922. The firm’s 50-day moving average price is $114.06 and its two-hundred day moving average price is $118.16. Abivax has a 52 week low of $5.69 and a 52 week high of $148.83. The company has a market capitalization of $8.16 billion, a P/E ratio of -19.62 and a beta of 0.69.

Abivax (NASDAQ:ABVX) last issued its quarterly earnings data on Friday, May 22nd. The company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.23. The business had revenue of $1.56 million during the quarter, compared to the consensus estimate of $0.40 million. As a group, analysts expect that Abivax will post -3.4 EPS for the current fiscal year.

Institutional Trading of Abivax

A number of hedge funds have recently bought and sold shares of ABVX. GHP Investment Advisors Inc. lifted its position in shares of Abivax by 155.6% during the first quarter. GHP Investment Advisors Inc. now owns 230 shares of the company’s stock worth $26,000 after purchasing an additional 140 shares in the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Abivax by 4,612.5% in the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock valued at $32,000 after purchasing an additional 369 shares in the last quarter. Bank of America Corp DE increased its holdings in shares of Abivax by 56.1% in the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock valued at $41,000 after purchasing an additional 1,990 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its position in Abivax by 661.5% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 396 shares of the company’s stock worth $53,000 after purchasing an additional 344 shares during the last quarter. Finally, WPG Advisers LLC raised its position in Abivax by 125.9% in the 4th quarter. WPG Advisers LLC now owns 454 shares of the company’s stock worth $61,000 after purchasing an additional 253 shares during the last quarter. 47.91% of the stock is owned by institutional investors.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.